MediGene touts new breast cancer data; Cayman Islands court to review WuXi buyout;

@FierceBiotech: Self-assembling DNA used in nanoscale delivery system. Article | Follow @FierceBiotech

 @JohnCFierce: Only a few days ago Pfizer researchers were describing tanezumab's PhIII data as "extraordinary." Today, not so much. | @JohnCFierce

> Germany's MediGene says that additional Phase II breast cancer data on EndoTAG-1 confirm a positive efficacy trend. MediGene release

> While GSK's leukemia drug Arzerra has been conditionally approved in the U.S. and the U.K., NICE says the NHS shouldn't have to pay for it. Story

> A Cayman Islands court will meet on Tuesday to review the $1.6 billion buyout of WuXi PharmaTech by Charles River Laboratories. Report

> Canada's Thallion Pharmaceuticals has paid $2.4 million to get out of its lease in Montreal as it scouts for a new headquarters. Story

> Bioheart says it has named Mike Tomas was named president and chief executive officer, replacing Karl Groth, who stays on as chairman. Tomas is president of The Astri Group, a private equity firm. The developer's last management shakeup took place less than a year ago. Report

And Finally... Xconomy has updated its guide to venture incubators. Report

Suggested Articles

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.

After its mega $424 million IPO this summer, blood cancer focused Legend Biotech is making a big change at the top.

Kymera Therapeutics has a great year, nabbing a $102 million round for its march to the clinic, and now wants a $100 million IPO.